{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:25:23Z","timestamp":1792783523149,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2021JJ40483"],"award-info":[{"award-number":["2021JJ40483"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Provincial Health Commission Program","award":["202211004530"],"award-info":[{"award-number":["202211004530"]}]},{"name":"Health Commission Program of Hunan province","award":["202203034469"],"award-info":[{"award-number":["202203034469"]}]},{"name":"Key Laboratory for Molecular Diagnosis and Precision Medicine in Hengyang","award":["202010041574"],"award-info":[{"award-number":["202010041574"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40121-022-00616-w","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T06:03:01Z","timestamp":1647237781000},"page":"1003-1017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical and Microbiological Characterization of Bloodstream Infections Caused by Mycoplasma hominis: An Overlooked Pathogen"],"prefix":"10.1007","volume":"11","author":[{"given":"Tong","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglin","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"616_CR1","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1128\/AAC.42.9.2304","volume":"42","author":"CM The B\u00e9b\u00e9ar","year":"1998","unstructured":"The B\u00e9b\u00e9ar CM, Renaudin H, Charron A, Bov\u00e9 JM, B\u00e9b\u00e9ar C, Renaudin J. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob Agents Chemother. 1998;42:2304\u201311.","journal-title":"Antimicrob Agents Chemother"},{"key":"616_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1128\/AAC.41.2.269","volume":"41","author":"CM Bebear","year":"1997","unstructured":"Bebear CM, Bov\u00e9 JM, Bebear C, Renaudin J. Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones. Antimicrob Agents Chemother. 1997;41:269\u201373.","journal-title":"Antimicrob Agents Chemother"},{"key":"616_CR3","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1128\/AAC.44.7.1980-1982.2000","volume":"44","author":"CM Bebear","year":"2000","unstructured":"Bebear CM, Renaudin H, Bryskier A, Bebear C. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother. 2000;44:1980\u20132.","journal-title":"Antimicrob Agents Chemother"},{"key":"616_CR4","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1128\/AAC.43.4.954","volume":"43","author":"CM Bebear","year":"1999","unstructured":"Bebear CM, Renaudin J, Charron A, et al. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis. Antimicrob Agents Chemother. 1999;43:954\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"616_CR5","doi-asserted-by":"publisher","first-page":"14854","DOI":"10.1038\/s41598-018-33260-x","volume":"8","author":"S Boujemaa","year":"2018","unstructured":"Boujemaa S, Ben Allaya A, Mlik B, Mardassi H, Ben Abdelmoumen Mardassi B. Phylogenetics of Mycoplasma hominis clinical strains associated with gynecological infections or infertility as disclosed by an expanded multilocus sequence typing scheme. Sci Rep. 2018;8:14854.","journal-title":"Sci Rep"},{"key":"616_CR6","doi-asserted-by":"crossref","unstructured":"Chalker VJ, Sharratt MG, Rees CL, et al. Tetracycline resistance mediated by tet(M) has variable integrative conjugative element composition in Mycoplasma hominis strains isolated in the United Kingdom from 2005 to 2015. Antimicrob Agents Chemother. 2021;65(4):e02513\u201320.","DOI":"10.1128\/AAC.02513-20"},{"key":"616_CR7","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1101\/gr.849004","volume":"14","author":"GE Crooks","year":"2004","unstructured":"Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: a sequence logo generator. Genome Res. 2004;14:1188\u201390.","journal-title":"Genome Res"},{"key":"616_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jgar.2018.04.003","volume":"14","author":"U F\u00fcrnkranz","year":"2018","unstructured":"F\u00fcrnkranz U, Walochnik J, Henrich B. Mycoplasma hominis shows strain-dependent increase in resistance to selected antibiotics after symbiosis with Trichomonas vaginalis. J Glob Antimicrob Resist. 2018;14:169\u201375.","journal-title":"J Glob Antimicrob Resist"},{"key":"616_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0163-4453(99)90109-3","volume":"39","author":"ML Fern\u00e1ndez Guerrero","year":"1999","unstructured":"Fern\u00e1ndez Guerrero ML, Manuel Ramos J, Soriano F. Mycoplasma hominis bacteraemia not associated with genital infections. J Infect. 1999;39:91\u20134.","journal-title":"J Infect"},{"key":"616_CR10","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1128\/AAC.49.3.1190-1193.2005","volume":"49","author":"D Gruson","year":"2005","unstructured":"Gruson D, Pereyre S, Renaudin H, Charron A, B\u00e9b\u00e9ar C, B\u00e9b\u00e9ar CM. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrob Agents Chemother. 2005;49:1190\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"616_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1752-1947-6-253","volume":"6","author":"AF Henao-Mart\u00ednez","year":"2012","unstructured":"Henao-Mart\u00ednez AF, Young H, Nardi-Korver JJ, Burman W. Mycoplasma hominis brain abscess presenting after a head trauma: a case report. J Med Case Rep. 2012;6:253.","journal-title":"J Med Case Rep"},{"key":"616_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","volume":"36","author":"TC Horan","year":"2008","unstructured":"Horan TC, Andrus M, Dudeck MA. CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309\u201332.","journal-title":"Am J Infect Control"},{"key":"616_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.5468\/ogs.2019.62.2.127","volume":"62","author":"YS Jang","year":"2019","unstructured":"Jang YS, Min JW, Kim YS. Positive culture rate and antimicrobial susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum. Obstet Gynecol Sci. 2019;62:127\u201333.","journal-title":"Obstet Gynecol Sci"},{"key":"616_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/jac\/dkn158","volume":"62","author":"N Kechagia","year":"2008","unstructured":"Kechagia N, Bersimis S, Chatzipanagiotou S. Incidence and antimicrobial susceptibilities of genital mycoplasmas in outpatient women with clinical vaginitis in Athens, Greece. J Antimicrob Chemother. 2008;62:122\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"616_CR15","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1111\/j.1469-0691.2010.03155.x","volume":"16","author":"R Krausse","year":"2010","unstructured":"Krausse R, Schubert S. In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20\u00a0years. Clin Microbiol Infect. 2010;16:1649\u201355.","journal-title":"Clin Microbiol Infect"},{"key":"616_CR16","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/molbev\/msw054","volume":"33","author":"S Kumar","year":"2016","unstructured":"Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33:1870\u20134.","journal-title":"Mol Biol Evol"},{"key":"616_CR17","first-page":"82","volume":"20","author":"C Leli","year":"2012","unstructured":"Leli C, Mencacci A, Bombaci JC, et al. Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in a population of Italian and immigrant outpatients. Infez Med. 2012;20:82\u20137.","journal-title":"Infez Med"},{"key":"616_CR18","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/clinids\/10.3.602","volume":"10","author":"S Madoff","year":"1988","unstructured":"Madoff S, Hooper DC. Nongenitourinary infections caused by Mycoplasma hominis in adults. Rev Infect Dis. 1988;10:602\u201313.","journal-title":"Rev Infect Dis"},{"key":"616_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1590\/S1517-83822014000100034","volume":"45","author":"DY Meng","year":"2014","unstructured":"Meng DY, Sun CJ, Yu JB, Ma J, Xue WC. Molecular mechanism of fluoroquinolones resistance in Mycoplasma hominis clinical isolates. Braz J Microbiol. 2014;45:239\u201342.","journal-title":"Braz J Microbiol"},{"key":"616_CR20","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1093\/jac\/dky238","volume":"73","author":"A Meygret","year":"2018","unstructured":"Meygret A, Le Roy C, Renaudin H, B\u00e9b\u00e9ar C, Pereyre S. Tetracycline and fluoroquinolone resistance in clinical Ureaplasma spp. and Mycoplasma hominis isolates in France between 2010 and 2015. J Antimicrob Chemother. 2018;73:2696\u2013703.","journal-title":"J Antimicrob Chemother"},{"key":"616_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/bioinformatics\/btw582","volume":"33","author":"M Nascimento","year":"2017","unstructured":"Nascimento M, Sousa A, Ramirez M, Francisco AP, Carri\u00e7o JA, Vaz C. PHYLOViZ 2.0: providing scalable data integration and visualization for multiple phylogenetic inference methods. Bioinformatics. 2017;33:128\u20139.","journal-title":"Bioinformatics"},{"key":"616_CR22","doi-asserted-by":"crossref","unstructured":"Noska A, Nasr R, Williams DN. Closed trauma, Mycoplasma hominis osteomyelitis, and the elusive diagnosis of Good\u2019s syndrome. BMJ Case Rep. 2012;2012:bcr2012007056.","DOI":"10.1136\/bcr-2012-007056"},{"key":"616_CR23","doi-asserted-by":"publisher","first-page":"103635","DOI":"10.1016\/j.micpath.2019.103635","volume":"135","author":"S Ozturk","year":"2019","unstructured":"Ozturk S, Yildiz S, Dursun P, Yener Ilce B, Kaymaz O. Mycoplasma hominis profile in women: culture, kit, molecular diagnosis, antimicrobial resistance, and treatment. Microb Pathog. 2019;135:103635.","journal-title":"Microb Pathog"},{"key":"616_CR24","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s10096-013-1892-y","volume":"32","author":"K P\u00f3nyai","year":"2013","unstructured":"P\u00f3nyai K, Mihalik N, Ostorh\u00e1zi E, et al. Incidence and antibiotic susceptibility of genital mycoplasmas in sexually active individuals in Hungary. Eur J Clin Microbiol Infect Dis. 2013;32:1423\u20136.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"616_CR25","unstructured":"Petti CA, Bosshard PP, Brandt ME, Clarridge JE, Procop G. Interpretive criteria for identification of bacteria and fungi by DNA target sequencing; approved guideline. Clinical and Laboratory Standards Institute (CLSI) document MM18-A. Wayne: CLSI; 2008."},{"key":"616_CR26","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/cid\/ciab061","volume":"73","author":"EL Plummer","year":"2021","unstructured":"Plummer EL, Vodstrcil LA, Bodiyabadu K, et al. Are Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum associated with specific genital symptoms and clinical signs in nonpregnant women? Clin Infect Dis. 2021;73:659\u201368.","journal-title":"Clin Infect Dis"},{"key":"616_CR27","doi-asserted-by":"publisher","first-page":"6026","DOI":"10.1128\/AAC.00895-15","volume":"59","author":"SC Schneider","year":"2015","unstructured":"Schneider SC, Tinguely R, Droz S, et al. Antibiotic susceptibility and sequence type distribution of Ureaplasma species isolated from genital samples in Switzerland. Antimicrob Agents Chemother. 2015;59:6026\u201331.","journal-title":"Antimicrob Agents Chemother"},{"key":"616_CR28","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801\u201310.","journal-title":"JAMA"},{"key":"616_CR29","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/cid\/ciw097","volume":"62","author":"BJ Smith","year":"2016","unstructured":"Smith BJ, Crowe A, Comahig J, Sheorey H, Stanley P. A 27-year-old woman with an unusual cause of periprosthetic joint infection. Clin Infect Dis. 2016;62:1463.","journal-title":"Clin Infect Dis"},{"key":"616_CR30","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1099\/jmm.0.000153","volume":"64","author":"J Song","year":"2015","unstructured":"Song J, Qiao Y, Kong Y, et al. Frequent topoisomerase IV mutations associated with fluoroquinolone resistance in Ureaplasma species. J Med Microbiol. 2015;64:1315\u201320.","journal-title":"J Med Microbiol"},{"key":"616_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.bpobgyn.2007.01.011","volume":"21","author":"D Taylor-Robinson","year":"2007","unstructured":"Taylor-Robinson D. The role of mycoplasmas in pregnancy outcome. Best Pract Res Clin Obstet Gynaecol. 2007;21:425\u201338.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"616_CR32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1471-0528.2010.02766.x","volume":"118","author":"D Taylor-Robinson","year":"2011","unstructured":"Taylor-Robinson D, Lamont RF. Mycoplasmas in pregnancy. BJOG. 2011;118:164\u201374.","journal-title":"BJOG"},{"key":"616_CR33","unstructured":"Waites KB, Bade DJ, B\u00e9b\u00e9ar C, et al. Methods for antimicrobial susceptibility testing for human mycoplasmas; approved guideline. CLSI standards: guidelines for health care excellence. Report No. M43-A. Wayne: Clinical and Laboratory Standards Institute; 2011."},{"key":"616_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1128\/CMR.18.4.757-789.2005","volume":"18","author":"KB Waites","year":"2005","unstructured":"Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev. 2005;18:757\u201389.","journal-title":"Clin Microbiol Rev"},{"key":"616_CR35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jmii.2014.06.007","volume":"49","author":"QY Wang","year":"2016","unstructured":"Wang QY, Li RH, Zheng LQ, Shang XH. Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in female outpatients, 2009\u20132013. J Microbiol Immunol Infect. 2016;49:359\u201362.","journal-title":"J Microbiol Immunol Infect"},{"key":"616_CR36","doi-asserted-by":"crossref","unstructured":"Yang T, Pan L, Wu N, et al. Antimicrobial resistance in clinical Ureaplasma spp. and Mycoplasma hominis and structural mechanisms underlying quinolone resistance. Antimicrob Agents Chemother. 2020;64(6):e02560\u201319.","DOI":"10.1128\/AAC.02560-19"},{"key":"616_CR37","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s10096-016-2745-2","volume":"35","author":"XY Zeng","year":"2016","unstructured":"Zeng XY, Xin N, Tong XN, Wang JY, Liu ZW. Prevalence and antibiotic susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in Xi\u2019an, China. Eur J Clin Microbiol Infect Dis. 2016;35:1941\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"616_CR38","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1099\/jmm.0.000913","volume":"68","author":"H Zhang","year":"2019","unstructured":"Zhang H, Zheng L, Zhao J, Ding S, Xia Y. Investigation of fluoroquinolone resistance mechanism in Mycoplasma hominis isolated from urogenital samples in a Chinese hospital. J Med Microbiol. 2019;68:206\u201310.","journal-title":"J Med Microbiol"},{"key":"616_CR39","first-page":"8842267","volume":"2021","author":"W Zhang","year":"2021","unstructured":"Zhang W, Li L, Zhang X, Fang H, Chen H, Rong C. Infection prevalence and antibiotic resistance levels in Ureaplasma urealyticum and Mycoplasma hominis in gynecological outpatients of a tertiary hospital in China from 2015 to 2018. Can J Infect Dis Med Microbiol. 2021;2021:8842267.","journal-title":"Can J Infect Dis Med Microbiol"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00616-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-022-00616-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00616-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T02:23:36Z","timestamp":1653099816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-022-00616-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["616"],"URL":"https:\/\/doi.org\/10.1007\/s40121-022-00616-w","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"assertion":[{"value":"23 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}